
366.4K
Downloads
255
Episodes
The Cardiovascular CME podcast is a free educational offering from Mayo Clinic, featuring content geared towards physicians, physician assistants, and nurse practitioners who are interested in exploring a multitude of cardiology-related topics. Tune in and subscribe to explore today’s most pressing cardiology topics with your colleagues at Mayo Clinic and gain valuable insights that can be directly applied to your practice. No CME credit offered for podcast episodes at this time.
Episodes

Tuesday Aug 09, 2022
Chronic Thromboembolic Pulmonary Hypertension
Tuesday Aug 09, 2022
Tuesday Aug 09, 2022
Chronic Thromboembolic Pulmonary Hypertension
Guest: Vidhu Anand, MBBS, FACC, FASE (@vidhu_anand)
Host: Malcolm R. Bell, M.D.
Patients with Chronic Thromboembolic Pulmonary Hypertension have a life expectancy of one to three years if left untreated. CTPH is usually caused by blood clots that are prolonged in the body for a certain period. In addition, the blood tends to back up into the lungs, which increases the patient's blood pressure. Some risk factors that can lead to CTPH are obesity, smoking, and cancer.
Joining us today to discuss Chronic Thromboembolic Pulmonary Hypertension is Vidhu Anand, MBBS, FACC, FASE, assistant professor of medicine at Mayo Clinic in Rochester, Minnesota.
Specific topics discussed:
- What is chronic thromboembolic pulmonary hypertension?
- How is it diagnosed?
- What are different treatment options for management of CTEPH?
Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV.
NEW Cardiovascular Education App:
The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today!
No CME credit offered for this episode.
Podcast episode transcript found here.